4-(2-(phenylsulfonylamino)ethylthio)-2-6-difluorophenoxyacetamide has been researched along with aniracetam* in 2 studies
2 other study(ies) available for 4-(2-(phenylsulfonylamino)ethylthio)-2-6-difluorophenoxyacetamide and aniracetam
Article | Year |
---|---|
A desensitization-selective potentiator of AMPA-type glutamate receptors.
1: We examined the effects of PEPA, an allosteric potentiator of AMPA receptors, on AMPA receptor kinetics. 2: PEPA did not affect the deactivation of glutamate responses but potently attenuated the extent of receptor desensitization without slowing the onset of desensitization in most of the recombinant AMPA receptors (GluR1-flip, GluR1-flop, GluR3-flip, GluR3-flip+GluR2-flip, and GluR3-flop+GluR2-flop) expressed in Xenopus oocytes. For the GluR3-flop subunit, PEPA attenuated the extent of desensitization and only weakly prolonged deactivation (1.3 fold). 3: PEPA did not significantly affect recovery from desensitization in oocytes expressing GluR3-flip, GluR1-flop, and GluR1-flop, but weakly accelerated (2.6 fold) recovery from desensitization in oocytes expressing GluR3-flop. 4: PEPA's effect on desensitization of GluR3-flop-containing receptors is unique in that onset is very slow. 5: Simulation studies using simplified kinetic models for AMPA receptors are utilized to explore the differential effects of PEPA on GluR3-flip and -flop. It is possible to simulate the action on GluR3-flip by modulating two rate constants in a 12-state kinetic model. For simulation of the action on GluR3-flop, the 12-state kinetic model is not enough, and it is necessary to invoke a 13th state, a PEPA-bound receptor to which glutamate cannot bind. 6: These results suggest that attenuation of extent of desensitization represents the principal mechanism underlying the potentiation of AMPA receptors by PEPA, and that PEPA exhibits different mechanisms with respect to GluR3-flip and GluR3-flop. Topics: Allosteric Regulation; Animals; Benzothiadiazines; In Vitro Techniques; Kinetics; Oocytes; Patch-Clamp Techniques; Phenoxyacetates; Pyrrolidinones; Rats; Receptors, AMPA; Xenopus | 2002 |
The AMPA receptor allosteric potentiator PEPA ameliorates post-ischemic memory impairment.
PEPA (4-[2-(Phenylsulphonylamino)ethylthio]-2,6-difluorophenoxyacetamide) is a recently developed allosteric potentiator of AMPA receptors that preferentially affects flop splice variants. We tested the effects of PEPA on ischemia-induced memory deficit in rats. Permanent unilateral occlusion of the middle cerebral artery induced severe impairment of performance of rats in the Morris water maze test. Repeated intravenous administration of PEPA (1, 3, 10 mg/kg/day for 10 days) improved test performance. In contrast, a corresponding dose of aniracetam, a representative potentiator of AMPA receptor, did not significantly improve test performance. Thus, PEPA is more effective than aniracetam in reversing impaired memory function as assessed by the Morris water maze test; and PEPA may be an effective compound for the treatment of impaired memory. Topics: Allosteric Regulation; Animals; Brain; Brain Ischemia; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Infarction, Middle Cerebral Artery; Male; Maze Learning; Memory Disorders; Nootropic Agents; Phenoxyacetates; Pyrrolidinones; Rats; Rats, Inbred SHR; Receptors, AMPA | 2001 |